Ed Arce
Stock Analyst at HC Wainwright & Co.
(2.35)
# 2,327
Out of 4,814 analysts
485
Total ratings
37.21%
Success rate
-1.76%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ed Arce
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MTVA MetaVia | Reiterates: Buy | $12 | $0.73 | +1,537.78% | 3 | Apr 16, 2025 | |
| UNCY Unicycive Therapeutics | Reiterates: Buy | $7.5 | $0.60 | +1,149.38% | 27 | Apr 11, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Buy | $60 | $10.51 | +470.88% | 31 | Apr 10, 2025 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $7.5 | $2.06 | +264.08% | 36 | Apr 4, 2025 | |
| IVA Inventiva | Reiterates: Buy | $13 | $3.36 | +286.90% | 16 | Apr 2, 2025 | |
| GALT Galectin Therapeutics | Reiterates: Neutral | n/a | $1.38 | - | 17 | Apr 2, 2025 | |
| TLPH Talphera | Reiterates: Buy | $6 | $0.48 | +1,162.63% | 6 | Apr 1, 2025 | |
| ALGS Aligos Therapeutics | Reiterates: Buy | $70 | $4.69 | +1,392.54% | 6 | Mar 31, 2025 | |
| DRRX DURECT | Reiterates: Neutral | n/a | $0.72 | - | 13 | Mar 27, 2025 | |
| ASMB Assembly Biosciences | Reiterates: Neutral | n/a | $9.70 | - | 8 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $0.36 | +3,205.79% | 17 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.46 | - | 24 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $2.21 | +1,347.96% | 11 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $35 | $19.44 | +80.04% | 22 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $75 | $37.65 | +99.23% | 25 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $29 → $21 | $6.07 | +246.25% | 22 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $72 | $38.63 | +86.38% | 30 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $400 → $405 | $301.73 | +34.23% | 17 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5.5 | $4.81 | +14.35% | 9 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $95 | $35.64 | +166.55% | 6 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $5.13 | +250.88% | 11 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $3.51 | +270.37% | 18 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $3.15 | +58.98% | 18 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $22 | $14.92 | +47.45% | 20 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $16.34 | +193.76% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $7.5 | $2.40 | +212.50% | 11 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $1.10 | +356.62% | 13 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $7.76 | +67.53% | 16 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 → $240 | $0.71 | +33,598.40% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $1.03 | - | 8 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $21.19 | +17.98% | 8 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.34 | - | 4 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $24.61 | - | 2 | Nov 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $7 | $23.83 | -70.63% | 1 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $26.94 | -22.05% | 1 | Sep 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.97 | - | 2 | Feb 15, 2017 |
MetaVia
Apr 16, 2025
Reiterates: Buy
Price Target: $12
Current: $0.73
Upside: +1,537.78%
Unicycive Therapeutics
Apr 11, 2025
Reiterates: Buy
Price Target: $7.5
Current: $0.60
Upside: +1,149.38%
Arcturus Therapeutics Holdings
Apr 10, 2025
Reiterates: Buy
Price Target: $60
Current: $10.51
Upside: +470.88%
Akebia Therapeutics
Apr 4, 2025
Reiterates: Buy
Price Target: $7.5
Current: $2.06
Upside: +264.08%
Inventiva
Apr 2, 2025
Reiterates: Buy
Price Target: $13
Current: $3.36
Upside: +286.90%
Galectin Therapeutics
Apr 2, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.38
Upside: -
Talphera
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $0.48
Upside: +1,162.63%
Aligos Therapeutics
Mar 31, 2025
Reiterates: Buy
Price Target: $70
Current: $4.69
Upside: +1,392.54%
DURECT
Mar 27, 2025
Reiterates: Neutral
Price Target: n/a
Current: $0.72
Upside: -
Assembly Biosciences
Mar 24, 2025
Reiterates: Neutral
Price Target: n/a
Current: $9.70
Upside: -
Mar 19, 2025
Reiterates: Buy
Price Target: $12
Current: $0.36
Upside: +3,205.79%
Mar 18, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.46
Upside: -
Mar 13, 2025
Reiterates: Buy
Price Target: $32
Current: $2.21
Upside: +1,347.96%
Mar 10, 2025
Maintains: Buy
Price Target: $24 → $35
Current: $19.44
Upside: +80.04%
Mar 3, 2025
Maintains: Buy
Price Target: $72 → $75
Current: $37.65
Upside: +99.23%
Feb 28, 2025
Reiterates: Buy
Price Target: $29 → $21
Current: $6.07
Upside: +246.25%
Feb 28, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $38.63
Upside: +86.38%
Feb 27, 2025
Maintains: Buy
Price Target: $400 → $405
Current: $301.73
Upside: +34.23%
Feb 21, 2025
Reiterates: Neutral
Price Target: $5.5
Current: $4.81
Upside: +14.35%
Feb 18, 2025
Reiterates: Buy
Price Target: $95
Current: $35.64
Upside: +166.55%
Feb 11, 2025
Reiterates: Buy
Price Target: $18
Current: $5.13
Upside: +250.88%
Feb 7, 2025
Reiterates: Buy
Price Target: $13
Current: $3.51
Upside: +270.37%
Jan 21, 2025
Reiterates: Buy
Price Target: $5
Current: $3.15
Upside: +58.98%
Jan 15, 2025
Maintains: Buy
Price Target: $18 → $22
Current: $14.92
Upside: +47.45%
Jan 14, 2025
Reiterates: Buy
Price Target: $48
Current: $16.34
Upside: +193.76%
Dec 4, 2024
Reiterates: Neutral
Price Target: $7.5
Current: $2.40
Upside: +212.50%
Sep 10, 2024
Reiterates: Buy
Price Target: $5
Current: $1.10
Upside: +356.62%
Sep 6, 2024
Reiterates: Buy
Price Target: $13
Current: $7.76
Upside: +67.53%
Mar 26, 2024
Reiterates: Buy
Price Target: $12 → $240
Current: $0.71
Upside: +33,598.40%
Mar 20, 2024
Upgrades: Neutral
Price Target: n/a
Current: $1.03
Upside: -
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $21.19
Upside: +17.98%
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.34
Upside: -
Nov 18, 2020
Downgrades: Neutral
Price Target: n/a
Current: $24.61
Upside: -
Nov 10, 2017
Assumes: Buy
Price Target: $7
Current: $23.83
Upside: -70.63%
Sep 11, 2017
Initiates: Buy
Price Target: $21
Current: $26.94
Upside: -22.05%
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $2.97
Upside: -